Ovarian cancer

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Who can joinAdults

Age18–70 years

Kind of studyObservational: no new treatment

What it testsWatches and records only

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

1 hospital in India taking patients for this trial.

Tata Memorial HospitalMumbai, MaharashtraDirections ↗

Registry summary (technical)

Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising therapeutic option for highly selected patients with peritoneal carcinomatosis arising from different malignancies such as colorectal cancer, gastric cancer, ovarian cancer, or peritoneal mesothelioma with improvement of both patient survival and quality of life. CRS, i.e., removal of all visible metastatic abdominal and pelvic disease with peritonectomy along with HIPEC (for 90…

Sponsor: Tata Memorial Centre
NCT02754115 on ClinicalTrials.gov
Last updated on the registry 21 Nov 2024 · read by us 20 Oct 2026

Ovarian cancer

Where to go

Need help reaching the trial team? Write to us.